

THROMBOSIS UK
(A Company Limited by Guarantee)
REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

Registered Charity No: 1090540

Company No: 4354472

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025

REFERENCE AND ADMINISTRATION DETAILS:

TRUSTEE AND MANAGEMENT

Trustees

Andrea Louise Croft

Dr Matthew Robert Fay

Professor Ian Maxwell Franklin (Resigned as Chair on 22.10.2024)

Simon Hart

Professor Beverley Jane Hunt OBE (Appointed as Co-Chair on 22.10.2024)

Stephane Jaglin

Professor Simon Noble (Retired 04.09.2025)

Robin Offord

Janet Morgan (Appointed as Co-Chair on 22.10.2024)

Nusaiba Masnurah

CEO

Jo Jerrome (Resigned effective from 31.08.2025)

Tiffany Richards, Interim CEO (Appointed on 05.08.2025)

Secretary

Professor Beverley Jane Hunt OBE

REGISTERED OFFICE

Couch Bright King & Co

2 Tolherst Court

Turkey Mill Business Park

Ashford Road

Maidstone

Kent ME14 5SF

AUDITORS

Couch Bright King & Co

Chartered Accountants

2 Tolherst Court

Turkey Mill Business Park

Ashford Road,

Maidstone

Kent ME14 5SF

SOLICITORS

Stone King

28 Ely Place

London EC1N 6TD

BANKERS

National Westminster Bank PLC

Maida Vale

Elgin Avenue

127 Kilburn Road

London NW6 6JL

THROMBOSIS UK

Registered Charity No: 1090540
Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025

The Trustees present their annual report and the financial statements for the year ended 31 January 2025.

The financial statements have been prepared in accordance with the accounting policies set out on pages 18 to 19, and comply with the Charities Act 2011, the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), published in October 2019 and the Companies Act 2006.

Thrombosis UK is a charitable company limited by guarantee, incorporated on 16 January 2002 and registered as a charity on 12 February 2002. It has no share capital. Accordingly, the report and financial statements also comply with the requirements of the Companies Act 2006.

Opening statement from Thrombosis UK co-chairs

For many years, we have been exceptionally fortunate to have stability at Thrombosis UK in terms of a dedicated team and board of trustees.

This year that changed. Our chair, Ian Franklin, who successfully led the charity for nine years, including the challenges of the pandemic, chose to step down, and our long-serving patient support and helpline lead Annya, left to pursue other interests.

Both individuals have made a lasting contribution to the organisation. Ian's calm and considered leadership has been immense. Over her 17 years, Annya has supported countless patients and family members better understand and adapt to life after VTE.

Throughout this time, the other employees and supporters of the charity continued to exceed expectations and ensure Thrombosis UK provides a breadth of support to our community. Thanks to that team, it has been a successful and busy year.

The charity has delivered a wide range of valuable and quality educational and patient support activities. We have continued our efforts to raise awareness of thrombosis and expanded our digital channels as a way to reach more people. We have also taken steps to enhance our governance and security and continue to support and undertake research.

With the changes within the charity and externally, it was with some trepidation that the two of us took on the responsibility of co-chairs. We are committed to continuing the work Ian began before the pandemic — reviewing our long-term strategy outlining how we best can save lives and prevent suffering caused by blood clots.

As we look to the year ahead, there is much to be proud of — and much still to do. Strengthening the charity's long-term sustainability will be a key focus, including exploring new ways to diversify and grow our income so that we can expand our reach and impact even further.

We would like to close with thanks. A heartfelt thanks to our fellow trustees and our employees, who have led the charity with resilience and purpose.

And to our supporters and volunteers — those individuals who take on amazing challenges and give so generously of their time. Without you, Thrombosis UK would not be here. Thank you to each and every one of you.

J Morgan & B Hunt

Co-Chairs, Thrombosis UK

THROMBOSIS UK

Registered Charity No: 1090540
Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025

OBJECTIVES AND STRATEGIES

Thrombosis UK was established to advance medical science in relation to the diagnosis, causes, prevention, alleviation, management, and cure of thrombosis and for the promotion of knowledge and public education of the understanding and awareness of thrombosis. Using the powers conferred by the Memorandum of Association, Thrombosis UK aims to fund:

- A range of studies looking at why and how a thrombosis occurs.
- Research into the management and the improvement of current treatments available.
- An education programme that informs people about the causes, effects, prevention, and recommended management of thrombosis.
- Provide a network of support for those affected by thrombosis.

ORGANISATION AND STRUCTURE

The Board of Trustees, who are also Directors of the company, govern Thrombosis UK.

The Trustees have the power to appoint, and remove any member, any member to act as Secretary to the Charity and all vote on the appointment of the Chair, Treasurer, and other Honorary Officers.

The charity seeks to ensure Trustees are appointed to fulfil the changing and on-going needs of the charity's activities and outcomes. A Trustee job description is agreed when vacancies become available to ensure existing and new Trustees have clarity on their roles and they each bring skills that complement and benefit Thrombosis UK.

New Trustees are appointed with the unanimous approval of existing Trustees. All Trustees give freely of their time and expertise and receive no remuneration for their work.

The day-to-day administration of the Charity is the responsibility of the Chief Executive Officer employed on a 0.8 permanent FTE contract. The current CEO resigned with effect from 31 August 2025, and an Interim CEO has been appointed with effect from 5 August 2025.

The Patient Support and Helpline Lead role is employed on a 0.8 permanent contract. This role has been vacant since 12 December 2024 pending review. The role of Admin and Fundraising Administrator on a 0.6 permanent contract, was increased to 0.8 from 1 September 2024, for the year under review. The role became vacant effective from 4 July 2025.

In 2022 the Charity appointed a Clinical Psychologist on a 0.5 two-year FTE contract starting 1 February 2022. Following review, this was extended in January 2024 for a further two years until 31 January 2026.

In September 2024, the Trustees appointed a temporary 0.4 Consultant as Operations Lead until 31 May 2025.

AIMS AND ACTIVITIES

The Charity aims to promote greater awareness and understanding of venous thromboembolism (VTE) to improve:

- Prevention of avoidable blood clots.
- Timely detection and prompt diagnosis of VTE.
- Appropriate management that improves patient outcomes.
- Timely support and education to enable patients to restore their well-being and health.

To support achievement of this, the Charity concentrates on three key areas.

- Awareness
- Education
- Research

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025

AWARENESS

Raising awareness remains a key objective of the charity's work, encompassing both specific awareness activities and creating opportunities through linked initiatives.

During 2024, the charity extended its reach and awareness through multiple activities, including:

- Exhibiting in Wales at several Aderiad's 'Let's Get Physical' campaign in Carmarthen and Wrexham.
- Having a table exhibition at the Royal Welsh Show.
- Presenting in-person and within online meetings to trainee medical students, nursing networks and industry/work settings.

Online, the charity reviewed its social media platforms, expanding to include Blue Sky and streamlining its LinkedIn presence via a business page. Next steps will be to expand training, focusing on design and AI, to promote engagement.

Working in collaboration with like-minded European patient groups to develop an awareness-raising social media campaign – 'Think Thrombosis' is due to launch in early 2025 and will consolidate key messages around awareness, knowledge and recognition of the common risks, signs and symptoms for blood clots.

In July 2024, the new Thrombosis UK website was launched. Developed following liaison and focus group meetings with stakeholders who regularly use the website, the new platform is much more user-friendly, easier to navigate, and provides increased opportunities for the charity, including an e-commerce shop, an accredited educational platform area, and can be largely managed by staff. Feedback in the first few months has been extremely positive from patient and HCP users.

Popular patient information resources have been refreshed with new designs but all in keeping with the Thrombosis UK brand and fresh new website, while those needing to be updated were completed during 2024 as well as new titles added – including Cerebral Venous Sinus Thrombosis (CVST), VTE in children and adolescents and, Thrombosis Prevention in Lower Limb Immobilisation. In the first quarter after launch, the site had welcomed just over 10,000 visits.

Monitoring site data, the team are pleased to see 'Organic Search' as one of the top ways the website is found, reflecting search engine results are 'finding' us! Direct, organic social and referral are the next most common.

THROMBOSIS UK

Registered Charity No: 1090540
Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025

Education

The charity is committed to advancing education and understanding of venous thromboembolism (VTE) among patients, healthcare providers, and the public.

In 2024, we continued to host the highly regarded 'National Thrombosis Week' (NTW'24) and 'Let's Talk Clots' (LTC'24) virtual conferences, while alongside these, we established regular online patient meetings and focused events.

Both virtual conferences received continuing professional development credits (CPD) from the Royal College of Pathologists.

NTW'24 featured 21 sessions, welcomed 54 faculty members, secured 17 CPD credits, and attracted 2,733 registrations from healthcare professionals. While primarily UK-based, our attendees represented 54 different countries! The conference incorporated webinars, small group 'round table' discussions, and an array of poster exhibitions and oral presentations. Feedback listed agenda topics, ease of access to live and catch-up recordings and CPD accreditation as the top three reasons delegates chose to register.

LTC'24 set a new record with 2,985 registrations from healthcare and allied professionals across 59 countries, demonstrating our global impact. Live webinar attendance ranged from 131 to 520, and follow-up recordings consistently drew over 940 views. Notably, we experienced increased interaction during the live week, with participants actively engaging in questions and discussions.

Despite facing unexpected challenges within the organisation from mid-2024, we successfully hosted 11 **Patient Information** sessions and regular 'Coffee and Chat' meetings. We were fortunate to have the support of leading specialists in VTE, including Prof Paul Bennett, Andrea Croft, Dr. Susie Shapiro, and Dr. Will Lester, alongside patient representatives, including ex-patient Trustee and patient advocate, Shaun Kinghorn.

Our Let's Talk Clots app has proven to be an invaluable educational resource, achieving 5,900 downloads and maintaining a remarkable 92% activity rate after download. The number of hospitals and medical settings promoting the app has surged, with rising requests for app posters and cards from primary care providers.

In August 2024, NHS Scotland endorsed eight Thrombosis UK patient resources, including app promotion postcards, with the NHS Healthier Scotland logo. This endorsement allows all Scottish medical settings to utilise these resources seamlessly, without needing local reviews. This achievement has been enthusiastically welcomed by both the Thrombosis UK team and Scottish VTE healthcare professionals.

THROMBOSIS UK

Registered Charity No: 1090540
Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025

RESEARCH

Phase One of the 'Detect VTE' project, aimed at overcoming barriers to the diagnosis of VTE, kicked off at the start of 2024. A total of 49 GP practices from across mainland UK volunteered to participate, collectively providing care for over 400,000 people. The initial audit was completed by June 2024, leading to an in-depth analysis of the data. We are grateful to have secured pro bono support from Costello Medical to assist us in this important work.

Detect VTE audit was the first of its kind, looking at the journey of individuals diagnosed with a VTE in the previous 12 months and their journey in the eight weeks prior to confirmed diagnosis. Looking at presentation symptoms, risk factors, and the number of presentations in the eight weeks before diagnosis was made, as well as where individuals presented during this journey. A paper detailing this work is due to be published in mid-2025.

The work could not have been accomplished without voluntary involvement from the primary practices and Thrombosis UK's Trustee and GP Lead, Dr Matthew Fay. This involvement should be both acknowledged and sincerely thanked. Following the audit, each practice received a detailed report of their practice's audit, was given the opportunity to have a 1-1 discussion session with the Medical Lead (Dr Matthew Fay) and an in-house educational session for all practice members. Approximately three-quarters requested the 1-1 feedback discussion, and around one-third, an educational event.

The work with Detect VTE now moves to Phase Two, and the development of an IT clinical tool to prompt investigation should suspicion of VTE be indicated.

Early work on a '**Stockings Off**' campaign, working in collaboration with the British Society for Haematology (BSH) has been initiated, with a freedom of information request (FOI) to NHS Procurement seeking to secure data on the number of compression stocking purchased by NHS England over a 12-month period (01/08/23-31/07/24).

Although not possible to have exact figures due to procurement pathways and variation in coding, we asked NHS Supply Chain (80 %+ ordered via them), who confirmed more than 2,726,723. Further work on the Stockings Off campaign is expected to start mid-2025.

The charity's involvement in research studies has increased with regular requests to secure '**Patient and Public Involvement**' (PPI). Patient supporters have been very interested in being involved, and the charity has hosted a range of online meetings, including:

- What is PPI? – intended for a patient audience.
- What PPI involvement should and should not include – intended for a healthcare professional audience.
- Individual collaboration with UK-TReN, HaemSTAR and Oxford University Hospitals on focused topics seeking PPI involvement and discussion on research design and priority areas for VTE-related research.

As interest and support have grown, Thrombosis UK's Professional Advisory Committee (PAC) worked to develop a 'Research Policy' for the charity, so that response to requests can always be balanced and reflect the values and focus of the charity.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025

REGAIN

Thrombosis UK's **REGAIN project** initially intended to provide free, online access to clinical psychological support for individuals diagnosed with Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT), but who were unable to access local psychological support. Since 2023, the emphasis of the REGAIN service has been to provide a general support service to people who have experienced a non-VITT-related thrombosis. The service has had three key foci:

1. Providing one-to-one or group support, directly working with people who have experienced some form of VTE.
2. Further developing the information provision accessible on the new website for people experiencing psychological distress following VTE and extending the focus to wider behavioural change.
3. Development of a training package for health professionals related to communication skills, initially available via the new website in a non-interactive format, and then as 'live' interactive workshops.

Individual/group support

Group support has been provided by a sequence of four weekly workshops over a period of a month, and repeated every three months. The first sequence has now been completed, and the next planned. Topics are coping with worry, panic, poor sleep and 'getting back to normal.'

Access to individual support has developed with increased prominence on the new website, although fewer I general are requiring additional support with the introduction of group sessions. However, some health care providers who were aware of the REGAIN service are utilizing the referral option patients (including some late-identified VITT patients) into one-to-one sessions and a wider group of clinicians.

Patient education

New and more detailed support booklets have been developed to support the existing psychological online information. These provide extended information on managing worry, panic and sleep. In addition, a 'how to stop' smoking information booklet has been developed as this appears to be a key concern for many VTE patients.

Health care professional education

A planned series of lectures, patient stories and health professional experiences focusing on a range of topics around the topic of communication are now being finalised in time for the new website. Six topics (including why bother to communicate, the basics of communication, and negotiating patient decision making) are being developed into an education package for health care professionals and expected to launch in 2025 with the intention that these will seek to secure CPD accreditation.

INTERNAL

The past year has been one of challenges, change and opportunities for Thrombosis UK. Time has been invested in securing the structure, including IT security and governance. Addition of new policies that safeguard, guide and formalise procedures, including the 'Abusive, Persistent or vexatious Complaints Policy.'

We have been extremely fortunate to secure pro bono support from two leading companies – Costello Medical, one of the most established independent agencies delivering medical communications and health economic services, and Curious Health, an exceptional team of healthcare digital communications specialists. Work with both continues and is making a significant impact on the outcome of projects that each has agreed to support.

It was also a year in which we said farewell to a long-serving member of staff, Annya Stephens Boal, who will be much missed by colleagues and the many patients and families who benefited from her knowledge, understanding and care during her 17 years of service to Thrombosis UK.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025

FUNDRAISING

Supporters took part in many events across the UK, and along with new we also welcomed repeat fundraisers and donors who so kindly continue to support Thrombosis UK.

Over the past year, fundraising efforts have secured over 80 unique events, which collectively raised a total of £89,227, averaging £1,115.34 per fundraiser. This impressive achievement is a testament to the dedication and generosity of our supporters.

Among the many incredible fundraisers, Lewis Owen led the way by raising an impressive £14,000. He was followed by Lauren James, who raised over £6,000, while Lyndsey Nichols contributed more than £3,500. Andrew Woods and Jane Enticott each raised just over £3,000. Their remarkable efforts have made a meaningful impact on the work of Thrombosis UK.

Review has indicated that marathons and runs are not only popular but have led to the raising of substantial funds, while walks, challenges, and general events have also made significant contributions. Although less 'popular' events such as skydives, climbs, and swims do impact awareness raising!

Continuing to diversify event opportunities maintains broad appeal; however, planning is key with so many events in spring and summer.

Thrombosis UK is immensely grateful to all who fundraise and donate to the charity for our work to continue. Tragically, support often comes after personal suffering or loss, and Thrombosis UK would like supporters and reiterate that their fundraising helps to make a significant difference to understanding, raising awareness of and supporting many individuals affected by venous thromboembolism. Due to their efforts, we can continue and be there for anyone at risk of, diagnosed with or who has lost a loved one due to VTE, to talk, share information and help them through the impact of thrombosis.

FINANCIAL REVIEW

During the year ended 31 January 2025 the charity made a deficit of £79,213 (2024: surplus of £255,442). Total incoming resources saw a decrease of 42% and expenditure increased by almost 48% in the year. The material decrease in incoming resources was as a result of Thrombosis UK successfully receiving restricted grant monies in year ended 31 January 2024 (see Note 3 on page 19).

The virtual events and activities incurred a generally lower expenditure requirement. A significant proportion of the increase in expenditure during the year was attributable to the charity's strategic decision to appoint a temporary consultant to fulfil the role of operations lead, alongside a higher number of travel fellowship grants awarded compared to the previous year. The economic and political uncertainty continues to affect the ability of the charity to meaningfully forecast corporate and individual funding commitments and, as with last year, although the charity budgeted to meet its planned charitable activities through funds raised in the year it was prepared to have to utilise a proportion of its general unrestricted reserves if necessary.

The net assets of the charity have been retained and have decreased from £667,220 in 2024 to £588,007 and this fits with the reserves policy of the charity. General unrestricted funds show a small deficit of £2,225 for the year.

The Statement of Financial Activities is presented on page 15.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025

PLANS FOR FUTURE PERIODS

The extended adoption of virtual events, in particular educational webinars, conferences, and meetings, has continued to enable the charity's work to grow and extend across:

- Reach.
- Global collaborations.
- Ease of access for patients, the general public and healthcare professionals to access information, support, and training.

The online platform has not only proven to be more cost-effective, but also received extremely positive feedback from faculty, attendees, and sponsors. While the recording of sessions ensured a lasting legacy to access high quality education.

The inaugural meeting for the newly formed Thrombosis UK 'Professional Advisory Committee' (PAC), was held in 2024. Formed with representatives from across the UK from health care and patient supporters, this committee will:

- To represent VTE stakeholders across the UK.
- Identify and inform Thrombosis UK on relevant and key areas of VTE which should be included in the charity's strategy for delivering its 'Awareness, Research and Care' goals.
- Provide input and guidance on update or development of resources, conference agendas and advocacy activities across the UK NHS systems.
- Be a first line referee for grant proposals or applications.
- Represent Thrombosis UK as an ambassador.

In reviewing plans for 2024/25, while Thrombosis UK is mindful of the benefits of personal interaction the charity is keen to enable increased access and the virtual platform and recording of webinars is currently enabling both greater access and a learning legacy. However, we are mindful that continued monitoring is important and so the charity, along with review from the PAC, will continue to carefully consider feedback, access and opportunity to ensure we are delivering in the most effective and efficient style suitable and welcomed by UK healthcare practitioners.

REFERENCE AND ADMINISTRATION DETAILS

A Board of ten Trustees, who are also Directors of the company, govern Thrombosis UK. The Trustees have the power to appoint and remove any member to act as Secretary to the charity and all - vote on the appointment of the Chairman, Treasurer, and other Honorary Officers. The charity seeks to ensure trustees are appointed to fulfil the changing and on- going needs of the charity's activities and outcomes. New trustees are appointed with the unanimous approval of existing trustees.

All Trustees give freely of their time and expertise and receive no remuneration for their work as trustees. The current list of trustees, who acted throughout the period of review, is given on page one.

Trustees unanimously agreed to adopt a rotational model for the role of Medical Director of Thrombosis UK, with each appointee in post for two to three years. In April 2016 Professor Simon Noble accepted an invitation to this role taking up the post in June 2016 until his retirement in 2025, with the objective of allowing for fresh ideas to percolate through the organisation. In November 2020 the Trustees agreed to extend retaining current directors for an extended 12 months while Governance work continued with the objective to write Trustee roles and job descriptions and develop a new Constitution. This work continues, and agreement was again in 2023 for this to be extended in order to implement a robust succession plan for Trustees so that skills, knowledge and experience are not lost, but instead, built on to secure the safe governance of Thrombosis UK.

Trustees' meetings are held a minimum of twice per year. Email correspondence is used to keep Trustees updated in between meetings and the CEO meets with Thrombosis UK's Medical Leads and /or Chair of Trustees between four-six times per year to discuss projects and agreed strategic and directional development.

THROMBOSIS UK

Registered Charity No: 1090540

Company No.: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025

TRUSTEES' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS

The trustees (who are also directors of Thrombosis UK for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for the year.

In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities Statement of Recommended Practice (SORP).
- Make judgements and estimates that are reasonable and prudent.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In accordance with company law, the Trustees certify that:

- so far as we are aware, there is no relevant audit information of which the company's auditors are unaware; and
- as Trustees we have taken all the steps that we ought to have taken in order to make ourselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

AUDITORS

The Auditors, Messrs Couch Bright King & Co., have expressed their willingness to continue in office and a resolution proposing their re-appointment will be put to the Trustees at the forthcoming Annual General Meeting.

SMALL COMPANY EXEMPTION

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

The Trustees who were in office on the date of approval of the financial statements have confirmed, as far as they are aware, that there is no relevant audit information of which the auditors are unaware. Each of the Trustees have confirmed that they have taken all the steps that they ought to have taken as Trustees in order to make themselves aware of any relevant audit information and to establish that it has been communicated to the auditors.

THROMBOSIS UK

Registered Charity No: 1090540

Company No.: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025

RESERVES POLICY

In the course of the development of the charity we will take account of the need to have reserves, and a policy, to honour future funding commitments that we make. We will also ensure that funds are sufficient to cover one year's charitable activity plus sufficient funds to cover all operating costs of the charity.

RISK ASSESSMENT

We consider the systems we have in place for the day-to-day operation of Thrombosis UK to be appropriate to our current size of operation, but we are aware that as we grow, we will need to develop and implement procedures and reporting regimes to mitigate the risks associated with running a charitable company.

PUBLIC BENEFIT

The Trustees confirm, to the best of their knowledge and belief, that they have complied with Section 4 of The Charities Act 2011 in respect of having due regard to Public Benefit Guidance published by the Charity Commission.

Approved by the Trustees on: 19th September 2025

Janet Morgan
Co-Chair



**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
THROMBOSIS UK
Registered Charity No: 1090540**

Opinion

We have audited the financial statements of Thrombosis UK for the year ended 31st January 2025 which comprise the primary statements such as the Statement of Financial Activities including Income and Expenditure Account, the Balance Sheet, the Statement of Cash flows and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Generally Accepted Accounting Practice including FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31st January 2025 and of its incoming resources and application of resources; including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice applicable to smaller entities;
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
THROMBOSIS UK
Registered Charity No: 1090540**

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the directors' report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the Trustees' Responsibilities Statement set out on page 10, the Trustees (who are also the directors of the charitable company for the purposes of the company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
THROMBOSIS UK**

Registered Charity No: 1090540

Auditor's responsibilities for the audit of the financial statements (.....Continued)

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

We have;


- Obtained an understanding of the legal and regulatory framework applicable to the entity and how the entity is complying with that framework;
- Obtained an understanding of the entity's policies and procedures on compliance with laws and regulations, including documentation of any instances of non-compliance;
- Identified the laws and regulations that have significance in the context of the entity;
- Obtained an understanding of the entity's risk assessment process, including the risk of fraud;
- Assessed and evaluated the susceptibility of the entity's financial statements to material misstatement, through error and fraud;
- Implemented procedures to enable the identification and testing of unusual or unexpected journal entries;
- Evaluated the assumptions and judgements used by management within significant accounting estimates and assessed if these indicate evidence of management bias;
- Tested significant transactions, in particular the evaluation of the business rationale for any which appear unusual or outside the company's normal course of business;
- Reviewed the financial statements and tested the disclosures against supporting documentation;
- Communicated relevant matters (including those above) to all members of the audit team to ensure they understood the risks specific to the entity and the audit procedures planned to mitigate these.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members as a body, for our audit work, for this report, or for the opinions we have formed.



Ms Tarwa Mohammed BA FCA (Senior Statutory Auditor)
For and on behalf of
Couch Bright King & Co
Chartered Accountants &
Statutory Auditors

2 Tolherst Court
Turkey Mill Business Park
Ashford Road, Maidstone
Kent ME14 5SF

29th September 2025

THROMBOSIS UK

Registered Charity No: 10905401

Company No: 4354472

STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account) FOR THE YEAR ENDED 31 JANUARY 2025

| | | Unrestricted | | | Year to 31.01.2025 | Year to 31.01.2024 |
|--|-------|-----------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| | Notes | General Funds £ | Designated Funds £ | Restricted Funds £ | Total Funds £ | Total Funds £ |
| Income: | | | | | | |
| Donations, legacies and gifts | 3 | 249,019 | - | - | 249,019 | 478,468 |
| <i>Income from Charitable activities;</i> | 4 | | | | | |
| Educational meetings | | 970 | - | - | 970 | - |
| Events - Sponsorship | | 20,356 | - | - | 20,356 | 23,750 |
| <i>Income from other trading activities;</i> | 5 | | | | | |
| Online shop | | - | - | - | - | - |
| Awareness Literature | | - | - | - | - | 630 |
| Other Income | | 337 | - | - | 337 | 703 |
| <i>Investment Income</i> | | | | | | |
| Bank Interest | | 22,544 | - | - | 22,544 | 3,367 |
| Total income | | 293,226 | - | - | 293,226 | 506,918 |
| Expenditure | | | | | | |
| Costs of raising funds | 6 | 4,908 | - | - | 4,908 | 4,702 |
| Costs of charitable activities | 7 | 290,543 | 740 | 76,248 | 367,531 | 246,774 |
| Total Expenditure | | 295,451 | 740 | 76,248 | 372,439 | 251,476 |
| Net income and Net movements in funds | | (2,225) | (740) | (76,248) | (79,213) | 255,442 |
| Transfers | | - | - | - | - | - |
| Net movements in funds | | (2,225) | (740) | (76,248) | (79,213) | 255,442 |
| Reconciliation of funds | | | | | | |
| Total funds At 1 February 2024 | | 382,307 | 740 | 284,173 | 667,220 | 411,778 |
| Total Funds At 31 January 2025 | 14 | 380,082 | - | 207,925 | 588,007 | 667,220 |

The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.

THROMBOSIS UK

Registered Charity No: 1090540
Company No: 4354472

BALANCE SHEET AS AT 31 JANUARY 2025


| | Notes | 2025 £ | 2024 £ |
|--|-------|----------------|----------------|
| Fixed Assets | | | |
| Tangible fixed assets | 10 | - | - |
| Current Assets | | | |
| Debtors | 12 | 17,312 | 22,027 |
| Cash at bank and in hand | | 586,045 | 667,574 |
| | | <u>603,357</u> | <u>689,601</u> |
| Creditors (amounts falling due within one year) | 13 | 15,350 | 22,381 |
| Net Current Assets | | <u>588,007</u> | <u>667,220</u> |
| Net Assets | | <u>588,007</u> | <u>667,220</u> |
| Represented by: | | | |
| Restricted funds | 14 | 207,925 | 284,173 |
| Designated Funds | 14 | - | 740 |
| Unrestricted funds | | | |
| General funds | 14 | 380,082 | 382,307 |
| Total unrestricted funds | | <u>588,007</u> | <u>667,220</u> |
| Total funds | | <u>588,007</u> | <u>667,220</u> |

The accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by the Trustees on 19th September 2025

Signed on their behalf by


Simon Hart
Trustee



Janet Morgan
Co-Chair

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

**STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 JANUARY 2025**

| | Note | 2025 £ | 2024 £ |
|--|------|-------------|-------------|
| Cash flows from operating activities: | | | |
| Net movements in funds for the year | | (79,213) | 255,442 |
| | | <hr/> | <hr/> |
| | | (79,213) | 255,442 |
| Movements in working capital | | | |
| Dividends and interest from investments | | (22,544) | (3,367) |
| Decrease/(Increase) in Debtors | | 4,715 | 5,912 |
| (Decrease)/Increase in Creditors | | (7,031) | 3,269 |
| | | <hr/> | <hr/> |
| Net cash generated by operating activities | | (104,073) | 261,256 |
| | | <hr/> | <hr/> |
| Cash flows from investing activities: | | | |
| Dividends and interest from investments | | 22,544 | 3,367 |
| | | <hr/> | <hr/> |
| Cash used in investing activities | | 22,544 | 3,367 |
| | | <hr/> | <hr/> |
| Increase in cash and cash equivalents | | (81,529) | 264,623 |
| Cash and cash equivalents at beginning of the year | | 667,574 | 402,951 |
| | | <hr/> | <hr/> |
| Cash and cash equivalents at the end of the year | 11 | 586,045 | 667,574 |
| | | <hr/> <hr/> | <hr/> <hr/> |

THROMBOSIS UK

Registered Charity No: 1090540
Company No: 4354472

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025

1) Statutory Information

a) Company Status

The charity is a company limited by guarantee, incorporated in England and Wales. The registered office is 2 Tolherst Court, Turkey Mill Business Park, Ashford Road, Maidstone, Kent ME14 5SF. The principal office address is PO Box 1242, Chew Magna, Bristol, BS40 8WG.

The members of the company are the trustees named on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

b) Charitable Status

Thrombosis UK is a registered charity, registration number 1090540 and in consequence is exempt from taxation on income arising from and expended on its charitable activities.

2) Accounting Policies

The principal accounting policies, all of which have been applied consistently throughout the year, are set out below:

a) Basis of Preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

Thrombosis UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

b) Functional and presentation currency

The company's functional and presentation currency is GBP.

c) Going Concern

The Trustees continue to adopt the going concern basis in preparing the financial statements and confirm there are no material uncertainties about the charity's ability to continue as a going concern.

d) Fixed Assets and Depreciation

Depreciation is charged on a straight-line basis, in order to write off the assets over their useful economic lives as follows:

Computer and Other Equipment over 3 years

Assets acquired under a value of £1,500 are charged to the Statement of Financial Activities in the year of acquisition.

e) Income and Expenditure recognition

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received, and the amount can be measured reliably. Income is deferred to match the period of the terms of the grant documentation or terms of agreement where applicable.

The Charity, in common with many others of a similar size and organisation, derives a substantial proportion of its income from voluntary donations. Such donations are recognised and entered into the accounting records when they are received. Other income, such as bank interest, is accounted for on an accruals basis.

On receipt, donated services are recognised on the basis of the value of the gift to the Charity which is the amount the Charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

All expenditure is accounted for on accruals basis.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025

- f) **Debtors and creditors receivable / payable within one year**
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.
- g) **Unrestricted Fund**
Unrestricted funds are donations, gifts and other incoming resources receivable or generated for the objects of the charity without further specified purpose and are available as general funds or for purposes as designated and agreed by all the Trustees.
- h) **Designated Fund**
Designated funds (where applicable) are unrestricted funds earmarked by the Trustees for particular purposes.
- i) **Restricted Fund**
Restricted funds are donations, gifts and other incoming resources receivable or are generated for the objects of the charity with a specified purpose. They can only be used in accordance with the donor's wish or by the terms of a public appeal.

| | <u>2025</u> £ | <u>2024</u> £ |
|-------------------------------|------------------|------------------|
| 3) Donations and gifts | | |
| <u>Restricted</u> | | |
| Research | - | 1,000 |
| REGAIN Programme | - | 753 |
| Education Grant | - | 16,000 |
| Detect VTE Audit Study | - | 255,020 |
| ISTH Grant 2022 | - | 28,673 |
| <u>Unrestricted</u> | | |
| Donations | 158,785 | 157,721 |
| Gift Aid | 14,046 | 19,301 |
| Donated Services * | 76,188 | - |
| | <u>249,019</u> | <u>478,468</u> |

The number of general donations we have received during the year has seen a small increase compared to prior year. Thrombosis UK is immensely grateful to all of those who have organised a fundraising event for the charity.

* Donated services comprise pro bono support received from Costello Medical, who provided research data analysis for the Detect VTE audit, and from Curious Health, who contributed communication and PR services in support of our awareness campaign.

| | <u>2025</u> £ | <u>2024</u> £ |
|--|------------------|------------------|
| 4) Income from charitable activities | | |
| Educational Meetings | 970 | - |
| Events - Sponsorship | 20,356 | 23,750 |
| | <u>21,326</u> | <u>23,750</u> |
| | ===== | ===== |
| 5) Income from other trading activities | | |
| Online shop – ebay sales | - | 703 |
| Awareness Literature | 337 | 630 |
| | <u>337</u> | <u>1,333</u> |
| | ===== | ===== |

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025

6) Costs of raising funds

| | | |
|-----------|--------------|--------------|
| Donations | 1,993 | 2,956 |
| Events | 2,915 | 1,746 |
| | <u>4,908</u> | <u>4,702</u> |

7) Analysis of costs of charitable activities

| | <u>Restricted</u> | <u>Designated / Unrestricted</u> | <u>2025</u> | <u>2024</u> |
|---------------------------|-------------------|--------------------------------------|----------------|----------------|
| | £ | £ | £ | £ |
| Research Grant | 54,207 | - | 54,207 | 6,097 |
| Travel Fellowship Grants | - | 12,100 | 12,100 | - |
| Awareness Resources | 10,755 | 28,857 | 39,612 | 26,806 |
| Awareness Literature | - | 12,929 | 12,929 | 40,492 |
| Thrombosis Education | - | 345 | 345 | 9,454 |
| Donated Services (Note 3) | - | 76,188 | 76,188 | - |
| Website & App Costs | - | 11,059 | 11,059 | 16,395 |
| Support Costs (Note 8) | 11,286 | 141,140 | 152,426 | 135,806 |
| Governance Costs (Note 8) | - | 8,665 | 8,665 | 11,724 |
| Total | <u>76,248</u> | <u>291,283</u> | <u>367,531</u> | <u>246,774</u> |

8) Analysis of Support and Governance costs

Thrombosis UK initially identifies its support costs which relate to the governance function and then the remaining support costs are apportioned as follows;

| | General Support £ | Governance Function £ | Total 2025 £ | Basis of apportionment |
|-------------------------------------|----------------------------------|--------------------------------------|-----------------------------|-----------------------------------|
| Trustee and other business meetings | - | 274 | 274 | Invoiced events |
| Salaries, wages and related costs | 121,888 | - | 121,888 | Allocated on time |
| General Office | 13,401 | - | 13,401 | Invoiced events |
| Audit fees | - | 6,930 | 6,930 | Governance |
| Consultancy Fees | 13,104 | - | 13,104 | Governance |
| Legal and other professional fees | 4,033 | 1,461 | 5,494 | Governance |
| | <u>152,426</u> | <u>8,665</u> | <u>161,091</u> | |

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025

Analysis of Support and Governance costs (.....Continued)

| | General Support £ | Governance Function £ | Total 2024 £ | Basis of apportionment |
|-------------------------------------|-------------------------|-----------------------------|--------------------|---------------------------|
| Trustee and other business meetings | - | 309 | 309 | Invoiced events |
| Salaries, wages and related costs | 124,538 | - | 124,538 | Allocated on time |
| General Office | 11,268 | - | 11,268 | Invoiced events |
| Audit fees | - | 6,600 | 6,600 | Governance |
| Consultancy Fees | - | - | - | Governance |
| Legal and other professional fees | - | 4,815 | 4,815 | Governance |
| | ----- | ----- | ----- | |
| | 135,806 | 11,724 | 147,530 | |
| | ----- | ----- | ----- | |

| | <u>2025</u> £ | <u>2024</u> £ |
|------------------------------|------------------|------------------|
| 9) Staff costs | | |
| Salaries | 110,682 | 113,260 |
| Employers National Insurance | 5,374 | 5,395 |
| Pensions | 5,832 | 5,883 |
| | ----- | ----- |
| | 121,888 | 124,538 |
| | ===== | ===== |

The average number employed during the year was

| | |
|----|----|
| 4 | 4 |
| == | == |

There are no employees with emoluments above £60,000.

The Key Management Personnel of the charity comprise the Trustees and the Chief Executive Officer. The Trustees have not received any remuneration for their work as Trustees. The total employee benefits of the Key Management Personnel were £49,720 (2024: £48,931).

10) Fixed Assets

| | <u>Computer Equipment</u> £ | <u>Total</u> £ |
|--|------------------------------------|-------------------|
| <u>Cost</u> | | |
| At 1 st February 2024 | 4,697 | 4,697 |
| Additions | - | - |
| | ----- | ----- |
| | 4,697 | 4,697 |
| | ===== | ===== |
| <u>Depreciation</u> | | |
| At 1 st February 2024 | 4,697 | 4,697 |
| Charge for year | - | - |
| | ----- | ----- |
| | 4,697 | 4,697 |
| | ----- | ----- |
| Net Book Value 31 st January 2025 | - | - |
| | ===== | ===== |
| Net Book Value 31 st January 2024 | - | - |
| | ===== | ===== |

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025

| | | | | | <u>2025</u> £ | <u>2024</u> £ |
|-----|--|---|----------------------------|----------------------------|------------------|---|
| 11) | Cash and cash equivalents | | | | | |
| | Cash at Bank | | | | 586,045 | 667,574 |
| | | | | | ===== | ===== |
| 12) | Debtors | | | | | |
| | Gift Aid | | | | 470 | 5,439 |
| | Prepayments & Accrued Income | | | | 16,842 | 16,588 |
| | | | | | 17,312 | 22,027 |
| | | | | | ===== | ===== |
| 13) | Creditors: Amounts falling due within one year | | | | | |
| | Other taxes | | | | 2,360 | 3,172 |
| | Grants Payable | | | | 2,900 | 7,900 |
| | Other creditor & Accruals | | | | 10,089 | 11,309 |
| | Deferred Grants | | | | - | - |
| | | | | | 15,350 | 22,381 |
| | | | | | ===== | ===== |
| 14) | Movement in Funds | | | | | |
| | | At 1 st February 2024 £ | Incoming Resources £ | Outgoing Resources £ | Transfers £ | At 31 st January 2025 £ |
| | Restricted funds: | | | | | |
| | Research | 6,459 | - | - | - | 6,459 |
| | REGAIN Programme | 12,960 | - | 12,960 | - | - |
| | VTE Grand Appeal | 3,143 | - | - | - | 3,143 |
| | ISTH | 14,069 | - | 10,755 | - | 3,314 |
| | Detect VTE Audit Study | 247,542 | - | 52,533 | - | 195,009 |
| | | ----- | ----- | ----- | ----- | ----- |
| | Total restricted funds | 284,173 | - | 76,248 | - | 207,925 |
| | | ===== | ===== | ===== | ===== | ===== |
| | Unrestricted funds: | | | | | |
| | Designated Funds | | | | | |
| | REGAIN Programme | 740 | - | 740 | - | - |
| | General Funds | 382,307 | 293,226 | 295,451 | - | 380,082 |
| | | ----- | ----- | ----- | ----- | ----- |
| | Total unrestricted funds | 383,047 | 293,226 | 296,191 | - | 380,082 |
| | | ===== | ===== | ===== | ===== | ===== |

Purpose of Restricted Funds

Research – There was no donation received towards the Thrombosis UK Research Fund in the year (2024: £1,000).

REGAIN Programme - The REGAIN Programme, launched by the charity in 2021, aims to address the psychological impact of Venous Thromboembolism (VTE), including complications associated with COVID-19. The initial development of the programme was funded by a restricted grant received in 2021, specifically allocated to support research and patient support activities relating to VTE and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). During the year, no further restricted income was received in relation to the programme (2024: £753). Total expenditure during the year amounted to £12,960, resulting in a closing restricted fund balance of £nil (2024: £12,960).

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025

Purpose of Restricted Funds (.....Continued)

ISTH – In 2023/24, Thrombosis UK received a restricted grant of approximately £28,500 (equivalent to \$37,500) from the International Society on Thrombosis and Haemostasis (ISTH) to support the development of a Venous Thromboembolism (VTE) Patient Information App, designed to improve patient access to essential information about VTE. No additional income was received during the year, and expenditure totalled £10,755. The restricted fund carried forward a closing balance of £3,314 at the year end.

Purpose of Unrestricted Funds

General funds balance includes:

(i) **Designated Funds – REGAIN Programme**

Following the launch of the REGAIN clinical psychology research service programme in 2021, the Trustees established a designated fund in the year ended 31 January 2022 to support the ongoing development and delivery of this programme. No additional income was received for the programme during the year (2024: £nil). This fund has been fully utilised in the year.

(ii) **General - Thrombosis UK is committed to raising awareness and advancing thrombosis research in the UK. The Trustees have decided that as much as possible of the money donated by the general public will be used towards these objectives.**

Events - Sponsorship fees received to enable the charity to widen the Public and Health Professionals' awareness of thrombosis and the related issues. Sponsorship fees of £20,356 were received in the year to support the National Thrombosis Week in May 2024 and the 'Let's Talk Clots' Virtual Conference held as part of World Thrombosis Day celebrations in October 2024.

Transfers between funds

There were no transfers between funds in the year.

15) Capital Commitments

There are no outstanding commitments as at 31 January 2025.

16) Contingent Liabilities

There are no contingent liabilities to report as at 31 January 2025.

17) Post Balance Sheet Events

There are no adjusting or non-adjusting events to report as at 31 January 2025.

18) Trustee Remuneration

The Trustees have not received any remuneration for their work as Trustees. Expenses totalling £274 (2024: £309) have been reimbursed to two Trustees.

19) Related Party Transactions

There were no Related Party Transactions in the year.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025

20) Taxation Status

The company being a registered charity (No.1090540) is not liable to Income and Corporation Taxes on its charitable activities.

21) Analysis of net assets between funds

| | Unrestricted Funds £ | Designated Funds £ | Restricted Funds £ | Total 2025 £ |
|------------------------------------|----------------------------|--------------------------|--------------------------|--------------------|
| Fixed assets | - | - | - | - |
| Cash and current Investments | 378,120 | - | 207,925 | 586,045 |
| Other current assets/(Liabilities) | 1,962 | - | - | 1,962 |
| | ----- | ----- | ----- | ----- |
| Total | 380,082 | - | 207,925 | 588,007 |
| | ===== | ===== | ===== | ===== |

| | Unrestricted Funds £ | Designated Funds £ | Restricted Funds £ | Total 2024 £ |
|------------------------------------|----------------------------|--------------------------|--------------------------|--------------------|
| Fixed assets | - | - | - | - |
| Cash and current Investments | 382,661 | 740 | 284,173 | 667,574 |
| Other current assets/(Liabilities) | (354) | - | - | (354) |
| | ----- | ----- | ----- | ----- |
| Total | 382,307 | 740 | 284,173 | 667,220 |
| | ===== | ===== | ===== | ===== |